BioMarin Pharmaceutical Inc. has announced the completion of its previously disclosed acquisition of Alesta Therapeutics B.V. The transaction, a share purchase, closed on August 31, 2026, making Alesta a wholly owned subsidiary of BioMarin.
Key Details
- Transaction: Completion of the acquisition of Alesta Therapeutics B.V. through a share purchase agreement.
- Effective Date: The acquisition was completed on August 31, 2026.
- Outcome: Alesta Therapeutics B.V. is now a wholly owned subsidiary of BioMarin Pharmaceutical Inc.